A new HIV treatment will soon come to market, and it will spearhead Merck’s attempt to be one of the leading drugmakers in a field

SAN DIEGO — Since Herceptin’s approval in 1998, breast cancer has been reshaped from a near-term death sentence into — in many cases — a

Carvykti shows promise in patients before full-blown multiple myeloma: Researchers from Dana-Farber Cancer Institute shared that 20 patients with high-risk smoldering multiple myeloma all saw

Companies looking to push the limits of artificial intelligence in healthcare are heading to Utah, where the state is giving them flexibility to use the

The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.